What Cancer Pathways Mean for the Biopharma Industry-Ellen Licking-05/22/2012 - 8:30am

Event Information
Event Topic: 
What Cancer Pathways Mean for the Biopharma Industry
Event Date: 
05/22/2012 - 8:30am
Event Location: 
Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library)
Speaker Information
Event Speaker: 
Ellen Licking
Event Speaker Title: 
Senior Editor and Analyst
Event Speaker Company: 
Value & Innovation LLC, a subsidiary of Real Endpoints
Event Speaker Bio: 

Ellen Licking

Ellen has covered the medical industry for more than 10 years, first as a reporter at BusinessWeek, then as a writer and editor for Windhover Information. Following Windhover’s acquisition by Elsevier in 2008, she worked as business bureau chief and executive editor for the pharma group, where she was responsible for both IN VIVO and Start-Up, among other duties. Ellen holds a BA in Biochemistry from Swarthmore College, an M. Phil. in Biochemistry from Cambridge University, and an MS in Biochemistry from Stanford University. (www.valueandinnovation.net)

Event Details
Event Details: 

Topic Description
Only a few years old, results from existing “cancer pathway” pilots underway at national and regional insurers are being unveiled in 2012. If these experiments in using evidence-based medicine to improve outcomes and lower costs prove successful, drug companies will have to adapt their drug development and commercialization strategies to drive market uptake of their products and retain pricing flexibility. And not just in oncology. The same lessons can be applied to other specialty diseases crowded with expensive treatment options, like multiple sclerosis, and rheumatoid arthritis.